| Autor: |
Bello-Rivero I; Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Crombet-Ramos T; Clinical Trial Directions, Center for Molecular Immunology (CIM), Havana, Cuba., Mesa-Pardillo C; Clinical Trial Directions, Center for Molecular Immunology (CIM), Havana, Cuba., Morera-Díaz Y; Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Mazorra-Herrera Z; Clinical Trial Directions, Center for Molecular Immunology (CIM), Havana, Cuba., Garcia-Rivera D; Clinical Trial Direction, Vaccine Finlay Institute (IFV), Havana, Cuba., Nodarse-Cuní H; Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Hernández-Bernal F; Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Muzio-Gonzalez V; Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Aguilera-Barreto A; Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Vazquez-Blomquist D; Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Domínguez-Horta MDC; Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Guillen-Nieto G; Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. |
| Abstrakt: |
The convergence of life sciences with neurosciences, nanotechnology, data management, and engineering has caused a technological diversification of the biotechnology, pharmaceutical, and medical technology industries, including the phenomenon of digital transformation, which has given rise to the so-called Fourth Industrial Revolution (Industry 4.0). Confronting the COVID-19 pandemic revealed the outstanding response capacity of the scientific community and the biopharmaceutical industry, based on a multidisciplinary and interinstitutional approach that has achieved an unprecedented integration in the history of biomedical science. Cuba, a small country, with scarce material resources, has had remarkable success in controlling the disease, which also highlights the impact of social factors. This report presents a summary of the most relevant presentations of selected topics during the scientific meeting, "BioHabana 2022: Cancer Immunotherapy and the COVID-19 Pandemic," which was held in Havana Cuba in April 2022. |
